Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia

Older patients with acute myeloid leukemia (AML) have worse rates of complete remission and shorter overall survival than younger patients. The epigenetic modifier CC-486 is an oral formulation of azacitidine with promising clinical activity in patients with AML in Phase I studies. The Phase III, ra...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Future Oncol
Main Authors: Roboz, Gail J, Montesinos, Pau, Selleslag, Dominik, Wei, Andrew, Jang, Jun-Ho, Falantes, Jose, Voso, Maria T, Sayar, Hamid, Porkka, Kimmo, Marlton, Paula, Almeida, Antonio, Mohan, Sanjay, Ravandi, Farhad, Garcia-Manero, Guillermo, Skikne, Barry, Kantarjian, Hagop
Formato: Artigo
Idioma:Inglês
Publicado em: Future Medicine Ltd 2016
Assuntos:
Clinical Trial Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5684733/
https://ncbi.nlm.nih.gov/pubmed/26785287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon.15.326
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados